Generation of antigen-specific paired heavy-light chain antibody sequences using large language models

Perry T. Wasdin[1,2,3], Nicole V. Johnson[4], Alexis K. Janke[3,5], Sofia Held[6], Toma M. Marinov[2,3], Gwen Jordaan[3,5], Léna Vandenabeele[6], Fani Pantouli[7], Rebecca A. Gillespie[8], Matthew J. Vukovich[3,5], Clinton M. Holt[1,2,3], Jeongryeol Kim[4], Grant Hansman[9], Jennifer Logue[10], Helen Y. Chu[10], Sarah F. Andrews[8], Masaru Kanekiyo[8], Giuseppe A. Sautto[7], Ted M. Ross[7], Daniel J. Sheward[6], Jason S. McLellan[4], Alexandra A. Abu-Shmais[3,5], Ivelin S. Georgiev[1,2,3,5,11-16,*]

[1]Program in Chemical and Physical Biology, Vanderbilt University Medical Center; Nashville, TN, USA

[2]Center for Computational Microbiology and Immunology, Vanderbilt University Medical Center; Nashville, TN, 37232, USA

[3]Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[4]Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712 USA

[5]Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[6]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

[7]Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, 34987 FL, USA

[8]Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

[9]Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, Gold Coast, QLD, Australia

[10]Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA

[11]Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN

[12]Department of Computer Science, Vanderbilt University, Nashville, TN

[13]Center for Structural Biology, Vanderbilt University, Nashville, TN

[14]Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

[15]Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA

[16]Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37237 USA

Abstract

Monoclonal antibodies represent a diverse class of proteins that, due to their exquisite specificity for their targets, are broadly and extensively used as therapeutics, diagnostics, and research reagents. Despite the critical importance of antibodies in a wide range of areas of biomedical significance, the traditional process of antibody discovery is limited by inefficiency, high costs and failure rates, fundamental logistical hurdles, limited scalability potential, and long turnaround times. Recent computational biology efforts, including machine learning/artificial intelligence (AI) approaches, have proven to have critical capabilities and advantages over purely experimental techniques, disrupting a number of areas that have traditionally met with limited success, such as protein structure modeling, enzyme engineering, drug design, and others (*1-3*). In the context of antibodies, AI-based approaches have been developed to optimize existing antibodies and generate novel antibody sequences in a target-agnostic manner (*4-6*). However, the ability of AI approaches to generate novel paired antibody sequences against a specific target (antigen) of interest has not been validated. In this work, we present MAGE (Monoclonal Antibody GEnerator), a sequence-based protein Large Language Model (LLM) fine-tuned for the task of generating paired variable heavy and light chain antibody sequences against antigens of interest. Here we show that MAGE is capable of efficiently generating diverse antibody sequences that are distinct from the antibody sequences found in the training datasets, with experimentally validated binding specificity against SARS-CoV-2 receptor-binding domain (RBD), an emerging avian influenza H5N1 viral hemagglutinin (H5), and respiratory syncytial virus A (RSV-A) prefusion F. MAGE is trained on protein sequence alone and requires only an antigen sequence as input for antibody design, with no need for a preexisting antibody template. MAGE represents a first-in-class model capable of designing human antibodies with demonstrated functionality against multiple targets. AI models for generation of human antibodies will provide unique and disruptive capabilities in the far-reaching field of antibody science.

Main Text

Introduction

Human monoclonal antibodies are a diverse class of therapeutics that can theoretically target any protein with exquisite specificity, making them promising candidates for treating a wide variety of diseases. Until recently, antibody development has been primarily driven by discovery-based experimental methods, typically through screening human or animal samples with prior exposure to an antigen target of interest. Even with recent developments that have drastically improved the throughput of antibody discovery methods, this process is laborious, slow, and cost-ineffective. The continued growth of the therapeutic market and range of applications for monoclonal antibodies presents an increased demand for *in silico* tools that accelerate and expand the capabilities of antibody discovery.

Recent breakthroughs in artificial intelligence (AI), most notably the unmatched performance of transformer-based Large Language Models (LLMs) and diffusion models on various tasks, have enabled a surge in computational approaches for antibody-related design tasks. Such methods include affinity maturation (*7, 8*), antibody redesign (*9-11*), and generation of single-domain antibodies (*4, 12*). However, no published methods have demonstrated the ability to design template-free, antigen-specific antibodies. Existing approaches are limited to antibody redesign, with a focus on generation of complementarity-determining regions (CDRs), requiring an initial antibody template to provide variable genes and framework regions for the antibody. Additionally, such models are primarily structure-based and require antibody-antigen complexes for training, which is significantly limiting due to insufficient data, especially in the context of paired, human antibodies.

In this manuscript, we present MAGE (Monoclonal Antibody GEnerator), a protein language model capable of generating paired heavy and light chain antibody variable sequences with binding specificity against input antigen sequences. MAGE was developed by finetuning an auto-regressive decoder LLM which was pretrained on general protein sequences. Such models learn from observed amino acid sequences by next-token prediction, using self-attention to capture complex dependencies within input sequences. Here, we leveraged this learned representation of amino acid sequences as a starting point for learning human antibody sequence features associated with binding specificity to diverse antigen targets. We show that MAGE is capable of generating antibodies that exhibit diverse sequence features, including heavy and light chain variable gene usage, levels of somatic hypermutation (SHM), and novel CDRs not observed in the training data. When prompted with SARS-CoV-2 wildtype receptor binding domain (RBD), binding specificity was successfully confirmed for 9/20 of experimentally validated MAGE-generated antibodies, including one antibody with better than 10 ng/mL potency of SARS-CoV-2 neutralization. Binding antibodies were also designed and validated against RSV-A prefusion F (7/23 antibodies), which was significantly less represented in the training data. We determined a cryo-EM structure of two MAGE-designed antibodies in complex with RSV F, demonstrating that MAGE generates antibodies with diverse binding modes and can incorporate impactful residues at key binding interfaces. Finally, MAGE-designed antibodies were validated against H5/TX/24 hemagglutinin (HA) (5/18 antibodies), demonstrating zero-shot learning capabilities against an influenza virus strain that was not present in the training data. MAGE therefore represents a first-in-class model capable of designing novel human antibodies with demonstrated functionality against antigen targets of interest, without having to provide any part of the antibody sequence as a starting template.

Results

Here, we present a protein language model (PLM) called MAGE, fine-tuned for generating paired heavy and light chain antibody variable sequences that bind to a prompted antigen sequence. Toward this goal, a pretrained model was finetuned on a training database containing antibody-antigen sequence pairs curated from literature and existing databases (**Fig. 1a**). In addition to published data, we collected an original dataset of antigen-specific antibody sequences against diverse viral antigens using LIBRA-seq (Linking B-cell Receptors to Antigen-specificity through Sequencing), a high-throughput method for identification of antigen-specific B cell receptors (BCRs) against an antigen panel(*13*). A panel of 18 diverse antigens was used to screen peripheral blood mononuclear cells (PBMCs) from 20 donors distributed across four groups (HIV infected, influenza vaccinated, COVID-19 convalescent, and healthy). Using this diverse training dataset, we aimed to present a model capable of generating functional, target-specific antibodies against input antigen sequences. General protein language models have been shown to have superior performance on antibody-specific tasks due to the complex nature of understanding the input antigens, antibodies, and the interactions between them (*11*). We therefore finetuned a general protein model for the task of antigen-specific antibody generation.

Generated antibody sequences are diverse and distinct from training data.

Following finetuning, the trained model could be prompted with an antigen sequence of interest to generate an output containing an antibody variable heavy and light chain sequence. To evaluate the ability of MAGE to generate antigen-specific antibody sequences, we selected three targets that spanned the range of training data representation. We first tested generation against SARS-CoV-2 RBD, which had disproportionately higher representation in the training data. Then, to show that the model can successfully work for antigen targets with less training data, we tested against two additional antigens. To assess the quality and diversity of sequences generated by MAGE, 1,000 antibody sequences were generated against RBD and aligned to a human germline reference using IMGT numbering(*14*) and then filtered using the following criteria (described in detail in Methods): 1) Removal of sequences without a recognizable heavy or light chain, 2) removal of sequences with any missing CDRs or framework regions (FWRs), and 3) removal of variable heavy or light sequences less than 100 amino acids in length. Almost all (991/1,000) of the generated sequences passed these filters. Additionally, sequences were scored for 'humanness' using the open-source platform BioPhi OASis(*15*). Based on suggested thresholds, sequences with an OASis percentile score less than 70% were removed, with only 2.2% (22/991) sequences falling below this humanness threshold (**Extended Data Fig. 1a)**. While these sequences could represent viable, particularly novel sequences, this model was intended to generate human antibodies for further characterization and these low-scoring antibodies by OASis were removed accordingly. In total, 969 of 1,000 generated sequences were retained for further analysis and down-selection for *in vitro* characterization.

The RBD-prompted sequences displayed diverse sequence features, using 37 unique variable heavy chain genes and 30 unique variable light chain genes, not accounting for different alleles. In total, 322 different pairs of heavy and light variable genes were represented in the generated sequences, with the most frequently used pair (IGHV3-53/66: IGKV1-33) representing only 13.9% (135/969) of sequences (**Fig. 1b**). Generated sequences also showed diverse CDRs, with heavy chain CDR3 (CDRH3) lengths ranging from 5 to 28 amino acids (mean = 16), and light chain CDR3s (CDRL3) lengths ranging from 7 to 12 amino acids (mean = 10) (**Extended Data Fig. 1c**). The light chains were more biased towards germline, with 50.1% (486/969) of containing no mutations, compared to 18.1% (175/969) for the heavy chains

(**Extended Data Fig. 1d**). These results suggest that rather than simply using a single dominant heavy-light chain combination, MAGE is capable of generating diverse populations of antibody sequences.

Figure 1. A General PLM was fine-tuned for antigen-specific antibody generation.



A) An Antigen-specific Antibody Database was curated, in combination with large scale LIBRA-seq datasets, in order to fine-tune the pretrained PLM for paired chain antibody generation against antigen prompts. B) Percentage of 1,000 antibodies generated against RBD that use each combination of heavy and light V genes. The top 10 most common genes are shown for each. C) Generated variable heavy (VH) and variable light (VL) sequences were aligned to the training data to find the minimum number of mutations between each generated sequence and any training sequence. D) For the most similar training sequence from the comparison in C, the distance was calculated between each region of the VH or VL sequence. The mean across all RBD generated sequences are shown with error bars representing the standard deviation.

We next sought to determine the novelty of generated antibodies at an individual level. In an attempt to quantify this novelty, each generated sequence was compared to all sequences seen during fine-tuning to identify the most similar training example based on the minimum Levenshtein distance between each pair of sequences. This distance, which can be intuitively interpreted as the number of amino acid differences, was first calculated separately for the heavy and light chains (**Fig. 1c**). We observed that the generated heavy chains contained more differences from training data sequences on average (mean = 11.7 differences), compared to light chains which exhibited substantially lower levels of differences (mean =

1.4 differences). When separated based on antibody sequence region, the distances to the nearest training sequence were highest in the CDR3s (**Fig. 1d)**, as could be expected due to the high diversity in this region. Distances were higher for the heavy chains than light chains across all regions aside from framework region 4 (FWR4). We also compared the similarity of generated heavy chain CDRH3s specifically to the training RBD sequences by finding the maximum sequence identity based on Levenshtein distance. The generated CDRH3s were largely novel, covering a range of identities centered at a mean of 72.4% sequence identity, with 7.4% of the generated antibodies containing CDRH3s identical to an antibody seen in training (**Extended Data Fig. 1a**). The distribution of similarity to training data based on both heavy and light chain distance and CDR3 identity was broad (**Extended Data Fig. 1e**), suggesting that the generated antibody sequences cover a range of uniqueness with respect to sequences seen in training. Together, these results indicated that MAGE generated sequences with differences in all regions of the antibody, rather than only designing CDRs.

Generated antibodies exhibit diverse binding profiles to SARS-CoV-2 RBD.

Following basic filtering of the 1,000 generated antibody sequences, we used a simple pipeline to select antibodies for experimental validation of binding (**Fig. 2a**). From the 969 antibody sequences that remained after filtering, 10 antibodies were first chosen in an unbiased manner, without comparison against RBD-specific antibodies: to test a diverse unbiased set, the 20th and 80th percentile of VH germline identity antibodies from sequences using the top 5 most frequently generated VH genes were selected. Another set of 10 antibodies was selected based on similarity to known RBD-specific antibodies: for this biased selection, the top 5 antibodies with the highest CDRH3 identity to any CoV-AbDab antibody, and top 5 antibodies with the highest VH identity to any CoV-AbDab antibody were chosen. In total, a set of 20 antibodies was selected for *in vitro* validation, containing a range of sequence characteristics and novelty which aimed to represent the distribution of generated sequences (**Supplemental Table 2**). When compared to the most similar training antibody, the selected antibodies ranged from a minimum VH distance of 3 residues (RBD-238) to 24 different residues (RBD-153) (**Fig. 2b)**. The respective light chains were more similar to those seen in training, with a minimum distance ranging from 0 residues (RBD-135) to 9 residues (RBD-727).

The 20 antibodies selected for experimental validation were tested for binding to RBD from the SARS-CoV-2 index strain by ELISA (enzyme-linked immunosorbent assay) (**Fig. 2c, Extended Data Fig. 2**). From these results, 9/20 (45%) of the tested antibodies were identified as binding hits for further characterization based on a minimum of 2-fold signal over background at the highest antibody concentration tested (10 μg/mL). In the biased selection group, 2/5 of the CDRH3 matches (RBD-159, RBD-951) and 4/5 of the VH matches (RBD-238, RBD-409, RBD-413, RBD-446) displayed binding by ELISA. In the unbiased selection group, 3/10 antibodies (RBD-61, RBD-404, RBD-839) displayed binding, with RBD-839 displaying the strong binding signal, on par with the positive control antibody S309(*16*). All of these binding antibodies showed no detectable ELISA signal to BG505, an HIV-1 envelope trimer. While the binding antibodies generally exhibited lower minimum distances from both VH and VL training sequences compared to the antibodies that showed no binding, the binding antibodies nevertheless exhibited substantial novelty, with a range of 5-25 (mean: 13.6) total distance to closest training antibody (**Fig. 2d**). In particular, RBD-839 showed a higher minimum distance from the nearest training antibody (total distance = 18 residues) than 67% of the non-binding antibodies (**Fig. 2d**). We

observed a wider range of VH distances to training data compared to VL, in alignment with the lower diversity of light chains we previously observed in the pool of generated antibodies and training data.

Figure 2. Twenty antibodies were selected for experimental validation of binding to RBD.



Twenty antibodies were selected for experimental validation of binding to RBD. A) Schematic of antibody selection method after generation, yielding a total of 20 antibodies for experimental validation. B) For each antibody, the Levenshtein distance for the VH or VL is shown in comparison to the training antibody with the lowest total distance (summed across VH and VL). Antibodies are grouped by selection group. C) ELISA area-under-the-curve (AUC) based on absorbance at 450 nm across a dilution series from 6.4x10-4 µg/mL to 10 µg/mL, with S309 (RBD-specific) positive control and VRC01 (HIV-1-specific) negative control antibodies. D) Relationship between the minimum VH and VLs distance from the closest training antibody sequences with points colored based on ELISA AUC. Overlapping points at VH distance = 4 and VL distance 5 are shown a single point with split coloring based on AUCs of these two antibodies (RBD-446, RBD-413). E) BLI sensorgrams for binding of high-affinity IgG antibodies to immobilized SARS-CoV-2 RBD-SD1. Data (black) were fit to a 1:2 bivalent analyte model. Curve fits are shown in red.

Binding was further validated using biolayer interferometry (BLI) to measure association and dissociation kinetics for IgG binding to immobilized, monomeric SARS-CoV-2 RBD (RBD-SD1) (**Fig. 2e, Extended Data, Fig. 3a)**. Apparent K_D (K_{D1}) values were determined by fitting the resulting binding curves to a 1:2 bivalent analyte model(*17*), which accounts for the slower observed dissociation rate due to avidity. Of the hits identified by ELISA, 8 of 9 demonstrated measurable binding to RBD-SD1, with no binding observed for RBD-404 at the highest concentration tested (1,024 nM). Four antibodies from the biased-selection groups (RBD-159, RBD-238, RBD-409, and RBD-951) and one from the unbiased-selection group (RBD-839) demonstrated apparent high-affinity binding, with K_{D1} values in the nanomolar to sub-nanomolar range. RBD-61, RBD-413, and RBD-446 also bound to RBD-SD1, albeit with reduced apparent affinity (**Extended Data Fig. 3b**). Although a small amount of non-specific binding was detected for one antibody (RBD-951, **Extended Data Fig. 3c**), for the other 7/8 antibodies no binding was observed by BLI to a prefusion-stabilized RSV F trimer (DS-Cav1(*18*)), which is consistent with the specificity observed by ELISA.

Although Figure 2d shows that the antibody sequences are distinct from the training data, exhibiting a range of novelty, we sought to assess how similar the generated binding antibodies are at the population level. Public antibody clones, commonly defined by matching variable genes and CDR3 identity >70%, represent a set of criteria for grouping similar antibodies found in different individuals that are likely to share the same binding specificity(*19-21*). When comparing the generated binding antibodies to antibodies from the CoV-AbDab using this definition, we found a range of 'publicness', from zero public clones for RBD-61 and RBD-404 to the highly public RBD-238 with over 100 public clones (**Fig. 3a**). We observed that all generated binding antibodies had >70% CDRH3 identity with at least one CoV-AbDab antibody, which is not surprising given the vast diversity and size of the database. Some of these antibodies, e.g. RBD-951, shared sequence features with many training antibodies at a population level, while others, e.g. RBD-61, appeared much less public (**Extended Data Fig. 4**). When comparing each generated binding antibody to its closest training match based on VH distance, we observed that the majority of differences were in the CDRH3, but almost all (8/9) of the binding antibodies contained at least one difference outside of the CDRH3 (**Fig. 3d**), demonstrating the ability of MAGE to generate distinct full variable sequences rather than only designing CDRs. In addition to varying levels of publicness and locations of mutations, we demonstrate that RBD-specific antibodies generated by MAGE have diverse sequence features including CDR lengths, variable gene usage, and humanness scores (**Fig. 3c**).

Generated RBD antibodies bind full-length spike and neutralize SARS-CoV-2.

The 9 binding antibodies to RBD were tested for binding to full-length SARS-CoV2 spike (index), along with a highly mutated variant (XBB.1) and SARS-CoV spike (SARS-1). Although MAGE was prompted using RBD only, we wanted to interrogate whether the generated antibodies would be compatible with and bind full-length spike. Of the RBD binding antibodies, 3/9 showed low to no binding to full-length spike in ELISA, suggesting that these antibodies may bind epitopes that are occluded or bind in conformations that may be sterically hindered on the spike trimers (**Fig. 3d**). All of the 6/9 antibodies which did bind to full-length spike also displayed binding to XBB.1, and two also displayed weak signal to SARS-CoV spike. These results further emphasize that MAGE was able to generate antibodies with diverse characteristics and binding properties, exhibiting cross-reactivity to different coronavirus spike variants.

Figure 3. Generated RBD binding antibodies have diverse sequence characteristics.



c

	Selection group	VH gene	VH germline identity	VL gene	VL germline identity	JH gene	JL gene	CDRH3	CDRL3	OASis Percentile
RBD-61	Unbiased	IGHV3-9	0.98	IGLV1-40	0.99	IGHJ2	IGLJ3	AKDYVPGNPWYFDL	QSYDSSLSGSV	0.92
RBD-839	Unbiased	IGHV1-69	0.98	IGLV3-25	1.0	IGHJ6	IGLJ3	ARGVVVVSATDDYYYYYGMDV	QSADSSGTYQV	0.91
RBD-159	CDRH3 identity	IGHV3-53	0.96	IGKV1-33	0.99	IGHJ6	IGKJ5	AREAFGMDV	QQYDNLPIT	0.97
RBD-404	Unbiased	IGHV3-53	0.96	IGKV1-33	1.0	IGHJ5	IGKJ5	AREGAVAGAPWFDP	QQYDNLPVI	0.82
RBD-409	VH identity	IGHV1-58	0.99	IGKV3-20	0.99	IGHJ3	IGKJ1	AAPNCNSTICYDGFDL	QQYGSSPWT	0.83
RBD-413	VH identity	IGHV3-53	0.99	IGKV1-9	0.98	IGHJ6	IGKJ4	AREVSYYGMDV	QQLNSYPPP	0.99
RBD-951	CDR3 identity	IGHV1-69	0.95	IGLV1-40	1.0	IGHJ4	IGLJ3	ARERGYSGYGSAYYFDY	QSYDSSLSGSV	0.92
RBD-446	VH identity	IGHV3-66	0.98	IGKV1-33	1.0	IGHJ6	IGKJ2	ARDLVKDGMDV	QQYDNLPL	0.95
RBD-238	VH identity	IGHV3-53	0.98	IGKV1-9	0.99	IGHJ6	IGKJ3	ARDLEVNGMDV	QQLNSYPG	0.94



Diversity and novelty of generated antibodies that bind RBD. Strong affinity binding antibodies are bolded. A) Publicness of binding antibodies based on CDRH3, VH, and both VH and VL. Clones defined as CDR3 identity > 70% and matching V genes for the specified chain. B) Sum of edits within each VH region for binding antibodies compared to closest sequence match in training data. C) Table showing sequence characteristics of RBD binding antibodies. OASis percentile represents a humanness score averaged across the heavy and light chains D) ELISA AUC for binding curve dilutions for SARS-CoV-2 WT and SARS-CoV-2 spikes for RBD binding antibodies. E) IC50 values for psuedovirus neutralization of SARS-CoV-2 variants for full spike binding antibodies. F) Full pseudovirus neutralization curves for RBD-409 against SARS-CoV-2 variants.

Following validation of binding by ELISA, we aimed to determine whether the generated antibodies also exhibited virus neutralization in a pseudovirus assay (*21*). Four of the RBD binding antibodies displayed neutralization against SARS-CoV-2 index pseudovirus, with RBD-409 displaying highly potent neutralization (IC_{50} = 6.7ng/mL) (**Fig. 3e, Extended Data Fig. 5**). Out of the 6 antibodies that bound full spike in ELISA, all but one showed neutralization potency of <1μg/mL against at least one spike variant. None of these antibodies were able to neutralize XBB.1.5, although this was unseen in training as the newest RBD variant included in training was Omicron BA.5. Nevertheless, RBD-409 displayed high neutralization potency against the SARS-CoV-2 spike Gamma (IC_{50} = 17ng/mL) and Delta (IC_{50} = 4.1 ng/mL) variants and was able to retain neutralization against several Omicron variants including BA.2, BA.2.75, and BJ.1 (**Fig. 3f**).

MAGE is capable of generating functional antibodies against diverse targets with lower representation in the training datasets

While the training dataset used to fine-tune MAGE was highly biased towards coronavirus antibody-antigen pairs, the dataset did contain other diverse antigen specificities to enable generation against different prompts. To that end, antibodies were designed and tested for binding against a newly emerging highly pathogenic avian influenza virus (*22*) (H5) and the RSV-A glycoprotein prefusion F (RSV-A). For RSV-A, there were 292 training antibodies against the exact RSV F sequence used for prompting, along with 753 antibodies against related RSV antigens including RSV-B and post-fusion RSV F. Hence, the number of exact prompt training antibodies for RSV-A represented approximately 1/10 of the size of the training antibodies for SARS-CoV-2 RBD. In addition to validating antibody designs against a target with limited training data, we also sought to test the capability of MAGE to generate antibodies against a target not seen in training (zero-shot). Toward this goal, we prompted MAGE using hemagglutinin from the avian influenza (H5N1 clade 2.3.4.4b virus), an emerging public health threat with multiple reported interspecies transmissions, including human infections (*22, 23*). While this exact antigen sequence was not seen in training and was not even reported at the time of training MAGE, a total of 472 H5N1-specific antibodies were included in training. These training antibodies were primarily specific to the hemagglutinin variant A/Indonesia/05/2005 (*24*), which has 91.5% sequence identity to the more recent A/Texas/37/2024 used for prompting. This target therefore represents a realistic use-case where MAGE can generate antibodies against an emerging threat without pre-existing knowledge of binding antibodies for that specific target antigen sequence.

To explore the behavior of MAGE when prompted with different antigens, 1,000 sequences were generated against A/cattle/TX/2024 H5 and RSV-A F. Notably, there was a significant enrichment of RSV-A and H5-specific clones generated when prompting with the respective antigens as opposed to prompting with SARS-CoV-2 RBD (**Fig. 4a**), suggesting that MAGE can enrich for prompt-specific antibody sequences. Further, each of the three prompts yielded antibody sequences with unique distributions of VH gene usage, with antibodies generated with the SARS-CoV-2 RBD prompt most frequently using IGHV3-53/66, in alignment with reported gene usage biases in SARS-CoV-2-specific repertoires(*25*), while RSV-A sequences heavily biased towards IGHV1-18 and H5 sequences towards IGHV4-34 (**Fig. 4b**). The antibody sequences generated against each prompt were then compared to the training data to find the minimum Levenshtein distance for each heavy and light chain, indicating that H5 and RSV-A prompted antibodies were more novel, on average, than the RBD prompted antibodies (**Fig. 4c-d**). Additionally, we found that the H5 and RSV-A prompted sequences exhibited higher levels of somatic hypermutation (SHM) than the RBD-prompted antibodies (**Fig. 4e-f**).

Figure 4. Characteristics of sequences generated against RSV and H5/TX/24 prompts.



A) Log fold changes showing increase in same antigen-specificity clones for RSV-A and H5/TX/24 prompts compared to WT RBD prompt. Calculated based on number of clones between generated and training antibodies, out of 1000 generated sequences. B) Heatmap showing percent of 1000 generated antibody encoding different variable genes for each antigen prompt. For 1000 generated antibodies against each prompt, the distribution of C) minimum VH Levenshtein distance to any training antibody, D) minimum VL Levenshtein distance to any training antibody, E) percent identity to VH germline, and F) percent identity to VL germline.

We next sought to experimentally validate the binding specificity for a subset of these generated sequences against the H5 and RSV-A prompts. For H5, we compared the generated sequences to H5 training antibodies and selected a validation set of 18 designed sequences for experimental validation, aiming to capture a range of novelty compared to the training examples seen (see methods section - *Antibody selection for experimental validation of H5N1 antibodies,* **Supplemental Table 2**). We confirmed strong binding by ELISA for 5/18 (28%) of these designs (**Fig. 5a**), along with another seven weak binding antibodies (>2-fold signal over background and >0.5 absorbance) at 10 µg/mL ELISA (**Extended Data Fig. 6a**). The minimum distance to training antibodies for the binding antibodies ranged from 4-16 residues for the heavy chain, and 1-8 residues for the light chain (**Fig. 5b**). The levels of SHM ranged from 6-11% for the heavy chain, and 7-8% for the light chain (**Fig. 5c**). Similarly to the antibodies designed against RBD, novel residues in these H5-prompted antibodies were found across the entire VH region (**Fig. 5d**) and were not limited to the CDRs. Notably, all five of the strong H5 binding antibodies were neutralizing against influenza strains A/Texas/37/2024, A/Vietnam/1203/2004, and A/Michigan/45/2015 (**Fig. 5e, 5f, Extended Data Fig. 6e-f**). Antibodies H5-242 and H5-384 were the most potent (IC_{50} < 100 ng/mL, **Fig. 5f**), with IC_{50}s comparable to the positive control CR9114, a potently and broadly neutralizing stem-binding antibody(*26*).

Figure 5. MAGE generates novel A/cattle/TX/2024 H5-binding antibodies.



A) Full ELISA dilution curves for designed antibodies against H5/TX/24 hemagglutinin. B) Percent somatic hypermutation in heavy and light chain for binding antibodies, calculated across VH and VL genes. C) Minimum distance to training antibody sequences. Distance represents number of residues different when compared to the heavy and light chain sequences from the training match with the lowest total distance (VH + VL). D) Edit distance by VH region to closest training sequence match from C). E) Neutralization dilution curves against H5/TX/24 hemagglutinin. F) IC_{50} values calculated from curves shown in panel E.

For the RSV-A prompt, we generated a larger pool of 10,000 antibodies, followed by selection for validation of biased and unbiased selections using a similar stratification method as used for RBD (see methods section - *Antibody selection for experimental validation of RSV antibodies*), yielding a set of 23 antibodies for experimental validation of binding (**Supplemental Table 2**). Following initial screening (**Extended Data Fig. 6b**), we confirmed binding by ELISA for 7/23 (30%) of these designs, including three antibodies that were selected without biasing towards known RSV-specific antibodies (**Fig. 6a**). While the seven binding antibodies had at least one heavy chain clone in the training data (>70% CDRH3 identity, same VH gene), they nevertheless included many variations throughout the heavy and light chains ranging from a minimum heavy chain distance of six residues for RSV-6479 to 21 residues for RSV-2954 (**Fig. 6b**). In the light chain, the distances compared to training sequences range from 4 for RSV-4314 to 12 for RSV-3301. The MAGE-designed RSV binding antibodies showed SHM levels ranging from 3-21% for the heavy chain, and 2-12% for the light chain variable region (**Fig. 6c**), suggesting that MAGE does not simply learn germline-level antibody sequences. Compared to the closest training antibodies, we see that the RSV binding antibodies included a range of differences across the VH regions, including differences in at least 4/7 regions for all seven binding antibodies (**Fig. 6d**). There was also a range of novelty for the light chains in this set of antibodies, with the minimum VL distance to training antibodies ranging from 4-12 residues. The binding antibodies were further characterized by pseudovirus neutralization assays (**Fig. 6e**). Notably, 3/7 of the binding antibodies were able to neutralize RSV-A (**Fig. 6e**); while IC_{50} values were not determined, RSV-2245 and RSV-4314 appeared to be strongly neutralizing with neutralization >50% at 0.1 μg/mL. Notably, RSV-2245 was from the unbiased

selection group, with a VH distance of 17 amino acids to the closest training antibody and a SHM level of 10%, representing a highly mutated antibody with a notably distinct sequence.

Figure 6. MAGE generates novel RSV-A binding antibodies.



A) Full ELISA dilution curves for designed antibodies against RSV-A pre-fusion. B) Minimum distance to training antibody sequences. Distance represents number of residues different when compared to the heavy and light chain sequences from the training match with the lowest total distance (VH + VL). C) Percent somatic hypermutation in heavy and light chain for binding antibodies, calculated across VH and VL genes. D) Distance by VH region to closest training sequence match from E) Antibody neutralization dilution curves against RSV-A.

To investigate the epitopes targeted by MAGE-generated antibodies from the unbiased selection group with both high levels of SHM and high distances from training, we determined a cryo-EM structure of RSV prefusion F (PR-DM(*27*)) bound to fragments of antigen binding (Fabs) for RSV-2245 and RSV-3301 (**Fig. 7a**). For this complex, 140,634 particles were extracted from 1,323 micrographs to generate a 3.4 Å resolution reconstruction with 3 copies of each Fab bound to the RSV F trimer. The structure revealed that RSV-2245 binds to an epitope primarily within prefusion-specific antigenic site V, burying 850 $Å^2$ on a single F protomer. Antibodies that target Site V are common in the human repertoire and tend to be potently neutralizing (*28*), consistent with the neutralization efficacy we observed for RSV-2245. RSV preF is contacted by all three CDRs of the RSV-2245 heavy chain and CDRs 1 and 2 of the light chain. The interface is centered on the strands of the β3-β4 hairpin, with a large network of hydrophobic contacts mediated by CDRH3 and Tyr53 of CDRH2. The sidechain of $Tyr53_{CDRH2}$ additionally contacts a single residue within β2, forming a hydrogen bond with the sidechain of $Tyr53_F$. The RSV-2245 light chain contributes additional interactions within β4 and with residues that flank the β3-β4 hairpin. Of note, $Asp30_{CDRL1}$, which is mutated from asparagine in the germline sequence, forms a salt bridge with the $Lys192_F$ sidechain. This mutation was only observed in 1/292 (0.34%) of the training RSV-specific antibodies, with the corresponding training antibody showing low similarity (73% LCDR1 identity and only 50% CDRH3 identity), demonstrating the ability of the model to learn sequence features from individual training sequences and integrate them into novel antibodies. The RSV-2245 epitope further

extends to include residues within antigenic Site II, mediated by polar contacts between CDRH2 and the helix-turn-helix formed by the α6 and α7 helices.

Figure 7. Cryo-EM structure of Fabs RSV-2245 and RSV-3301 bound to RSV-A F



A) Overview of 3.4 Å resolution cryo-EM structure of RSV F bound to fragments of antigen binding (Fabs) for RSV-2245 (heavy and light chains in dark and light blue, respectively) and RSV-3301 (heavy and light chains in dark and light green, respectively). RSV-A F protomers are shown in shades of pink. Zoomed-in views of the Fab-RSV F interface are shown as cartoons with select residues represented as sticks for B) RSV-2245 heavy chain, C) RSV-2245 light chain, D) RSV-3301 heavy chain, and E) RSV-3301 light chain. Hydrogen bonds are shown as dashed blue lines.

RSV-3301 represents the most highly mutated antibody of the validated RSV-specific set. The structure revealed that RSV-3301 buries approximately 715 $Å^2$ within the membrane-proximal lobe of one F protomer, targeting an epitope that lies almost entirely within antigenic Site I. This site is typically considered to be postfusion F-specific but is largely conserved in both pre- and postfusion conformations(*29-31*). The interaction is dominated by CDRH3, which extends into the cavity formed between the α8 helix and the curved β-sheet formed in part by β10, β9, β7, and β2. Backbone atoms within $Asp99_{CDRH3}$ and $Arg100_{CDRH3}$ form hydrogen bonds with the sidechains of $Asn380_F$ and $Asp344_F$, respectively, bridging α8 and β9. Notably, $Arg100_{CDRH3}$ was observed in training antibodies but was not found in the most similar training antibody (VH distance = 12) despite having a highly similar CDRH3 (94.4% identity). CDRH1 and CDRH2 make polar and hydrophobic contacts within and proximal to the α8 helix, including two salt bridges formed between $Arg32_{CDRH1}$ and $Glu378_F$ and $Asp58_{CDRH2}$ and $Lys390_F$. The RSV-3301 light chain also buries surface area on F between α8 and β2, primarily through hydrophobic contacts mediated by $Tyr32_{CDRL1}$ and $Tyr92_{CDRL3}$. Additionally, CDRL1 and LFR3 contact residues within β22, extending the RSV-3301 epitope into antigenic Site IV.

Together, the structural characterization of these two antibodies demonstrates that MAGE generates antibodies with diverse binding properties. Not only do RSV-2245 and RSV-3301 target different binding sites of the RSV-A F protein, but these two antibodies display different binding properties. RSV-2245 contains binding residues distributed across both the heavy and light chains, whereas RSV-3301 binding

is dominated by interactions within CDRH3. Although both antibodies contained MAGE-generated mutations in key binding residues, there were many mutations introduced into framework regions that did not interface with the antigen surface. To test the impact of these non-germline mutations, we reverted the VH genes to germline and tested for binding by ELISA, with the germline-reverted RSV-3301 showing substantial reduction in binding by ELISA, while germline-reverted RSV-2245 retained comparable binding to its fully mutated form (**Extended Data Fig. 7a-b**). Further, BLI was used to characterize the binding of RSV-2245 Fab and RSV-3301 Fab to immobilized RSV-A F (**Extended Data Fig. 7c-d**). For RSV-2245, a 1:1 binding model was used to determine binding affinity *(K_D* = 1.5×10^{-7} M). Due to suspected heterogeneity in the epitope targeted by RSV-3301, these data were fit to a heterogeneous ligand model to determine two K_D values (K_{D1} = 6.7×10^{-6} M and K_{D2} = 4.5×10^{-9} M). Together, these results show that MAGE can generate antibodies with a variety of SHM changes in different regions of the antibody sequence and with differing impacts on antigen recognition and binding affinity.

Discussion

In this work, we aimed to develop a purely sequence-based model capable of generating paired heavy-light chain antibody sequences with prompt-specific binding. Once trained, the MAGE model presented here requires no template antibody or protein structural information. When prompted with an antigen amino acid sequence, MAGE produces full human variable heavy and light chains, including novel designs with changes from germline sequence introduced throughout the entire variable sequences. Our results confirm that generative LLM models like MAGE are capable of the complex task of generating full paired heavy and light chain antibody sequences, demonstrating validated binding against RBD, H5 hemagglutinin, and RSV-A prefusion F. MAGE-generated antibodies showed diverse sequence characteristics and binding properties, including potent neutralization for a subset of the binding antibodies designed against each antigen. While MAGE is not conditioned on neutralization, this demonstrates the functionality of these antibodies and validates the ability of MAGE to produce useful, clinically relevant antibodies in the context of therapeutic discovery. For RBD and RSV-A, a subset of validated, target-specific designs were selected with no bias towards known antibodies, demonstrating design of potently neutralizing antibodies without the need for a starting template antibody sequence or structure. The design of neutralizing antibodies against H5/TX/24 hemagglutinin demonstrates zero-shot learning capabilities, where MAGE was able to generate antibodies against an unseen influenza strain by training on previously characterized antibodies with specificity against a related, but divergent H5N1 strain. This demonstrates a realistic use-case for this approach, where MAGE could be used to generate antibodies against an emerging health threat more rapidly than traditional antibody discovery methods that would rely on access to specialized biological materials (e.g. blood samples or antigen protein).

The antibodies designed and characterized here display a range of sequence characteristics, including differential gene usage, CDR properties, and levels of SHM. While a subset of the validated binding antibodies have CDRH3s that are similar to those seen in training, it is well-established that individual amino acid substitutions can disrupt antibody-antigen binding(*32, 33*), even within non-interfacing framework regions(*34, 35*). As such, the ability of the model presented here to generate binding – and in some cases potently neutralizing – antibody sequences highlights the utility of generative algorithms in creating solutions that differ from those seen in the training data while retaining antibody-antigen recognition properties. In addition to designs with low numbers of edits introduced to training antibodies, we also validated binding for more novel antibodies with >20 total amino acid differences to the most similar training examples (RSV-2245 and RSV-3301). Structural characterization of these antibodies

showed that they target different sites on RSV F with different modes of binding which utilize residues not found in the closest training antibody matches. Additionally, the Site I epitope targeted by RSV-3301 is not well characterized and, to our knowledge, this is the first structure showing a human antibody targeting this epitope in prefusion F(*36*).

We emphasize that MAGE is not restricted to redesigning existing antibodies, rather it is able to sample the distribution of known binding sequences to learn the complex sequence features associated with antigen-binding specificity and then generate a pool of diverse antibodies that is highly enriched for binding antibodies, providing candidates for further characterization, down-selection, and development. In this study we have only sampled a fraction of this sequence space for validation but envision that this candidate pool could be further mined to find antibodies with desired properties that have not yet been explored.

In this work, MAGE was validated against viral antigen targets as a proof-of-concept. However, data generation methods are constantly improving, and large-scale efforts using high-throughput methods such as LIBRA-seq could soon yield datasets of sufficient scale for training such models to efficiently generate antibodies against diverse antigen targets beyond what is included in the training datasets. The development of these datasets, along with the subsequent experimental validation of generated antibodies which can be incorporated into training data, will enable iterative improvement of MAGE. Since applications of LLMs in other fields have shown evidence of generalization (*37-39*), we anticipate that, provided enough data, models such as MAGE could be capable of learning the more general rules of residue-level interactions that govern antibody-antigen binding with the capability to generate antibodies against completely unseen targets. Such approaches will have the potential to revolutionize the field of antibody discovery, but the generalizability of such models is yet to be proven in this context. Despite these limitations, the model described here presents the first example of an LLM capable of antigen-specific paired heavy-light chain antibody sequence generation and provides a promising glimpse into the future of AI-accelerated antibody discovery.

Acknowledgements

We thank all members of the Georgiev laboratory for their support and feedback. For work described in this manuscript, I.S.G., A.A.A.-S., M.J.V., and P.T.W. were supported, in part, by the G. Harold and Leila Y. Mathers Charitable Foundation (MF-2107-01851), NIH R01AI175245, and NIH R01 AI152693 (to I.S.G.). S.H., L.V., and D.S., were supported by funding from the Swedish Research Council (2018-02381 and 2023-02516 to Ben Murrell, Karolinska). This work was partly funded by Welch Foundation grant number F-0003-19620604 (J.S.M.). We thank Ben Murrell for feedback on the manuscript. We thank Vito Quaranta and Darren Tyson for providing computational resources through the Quantitative Systems Biology Center. We thank the Vanderbilt Technologies for Advanced Genomics Core (VANTAGE), which is supported in part by CTSA (5UL1 RR024975-03), for providing technical assistance with library production and sequencing. We would like to thank Mark Connors for providing HIV-1 PBMC samples. Biorender was used for creating schematic figures. The funders had no role in the conceptualization or execution of any studies or drafting of the manuscript.

Author contributions

P.T.W., T.M.M., and I.S.G. conceived the project. P.T.W. and I.S.G. devised the research strategy, interpreted the results, and wrote the manuscript. P.T.W. performed computational analysis including

model fine-tuning and development of the computational analysis pipelines for inputs and outputs of the model. A.A.A-S. organized experiments for characterization of designed antibodies and performed the LIBRA-seq experiments for data generation. G.H., J.L., H.Y.C., G.A.S., and T.M.R. provided patient PBMC samples for LIBRA-seq experiments. A.A.A-S, A.K.J., G.J., and M.J.V. performed antibody expression, purification, and ELISA assays. N.V.J., J.R.K., and J.S.M. performed biolayer interferometry experiments and cryo-EM structure determination. S.H., L.V., and D.J.S. performed pseudovirus neutralization assays for RBD. R.A.G., S.F.A, and M.K. performed neutralization assays for H5 hemagglutinin and analyzed data. G.A.S. and F.P. performed RSV neutralization assays. P.T.W, C.M.H., and T.M.M performed database curation and data cleaning. I.S.G. acquired funding for this work. All of the authors reviewed and approved the final manuscript.

Methods

Database curation

Paired antibody sequences with antigen specificity labels were curated from public databases and literature, primarily the CoV-AbDab, PlAbDab, and SabDab. (*40-42*) For the PlAbDab, due to vague antigen labels (e.g. "flu"), sequences were manually curated from referenced literature. (*24, 28, 43-47*) Sequences were also sources from previously published LIBRA-seq datasets (*13, 48-50*) and other recent literature.(*51, 52*) For all training sequences, heavy and light chains less than 100 amino acid residues in length were removed. When not provided by sources, antigens sequences were obtained from Uniprot(*53*). For all antigen sequences, signal peptides were removed using SignalP 6.0.(*54*) See provided Python scripts and **Supplemental Data Table 1** for further details on filtering applied for individual sources and total counts for antigens and sources included in training.

Antibody generation and basic filtering

For generation of antibodies against an antigen target, the fine-tuned model was prompted with the entire antigen amino acid. The generated antibody sequences were annotated using ANARCI(*55*) with IMGT(*14*) numbering. If a sequence had either a heavy or light chain that was not recognized as a human variable chain by ANARCI, it was discarded, along with any sequences missing framework or CDR regions following alignment. Heavy chains or light chains shorter than 100 amino acids were also discarded, although few sequences under these lengths survived the previous filtering steps. Heavy chains which were identical to a training example were discarded, although there was only one occurrence of this in the sequences generated against SARS-CoV-2 RBD. Finally, antibodies were assessed for mutational load based on identity to germline variable genes, and humanness using the BioPhi OASis software.

Perplexity was calculated by performing a backward pass through the trained model, with the model in evaluation mode, to calculate the exponential of the average negative log-likelihood for each generated sequence.

Antibody selection for experimental validation of RBD antibodies

In addition to the basic filtering outlined above, additional criteria were applied to select candidates for experimental validation. For the heavy variable gene, only sequences with >85% identity were retained. For humanness, sequences below 70th percentile were discarded based on the recommended threshold for OASis(*15*). In order to test novel sequences generated by the model, antibodies with a CDRH3 identical to any training example (n = 72), or a VH germline identity of 100% (n = 175) were removed, leaving a selection pool of 732 antibodies. In addition, any sequences with both >90% VH identity and >90%

CDRH3 identity to CoV-AbDab RBD binding antibody sequences were removed. Following these filtering steps, the following automated selected pipeline was applied:

1. From the top 5 most frequently generated VH genes, select sequences with 20th and 80th percentile VH identities.
2. Select top 5 sequences by rank of maximum CDRH3 identity to known binding antibodies.
3. Select top 5 sequences by rank of maximum VH identity to know binding antibodies.

Together, these three selection steps yield 20 antibodies per antigen target. Antibodies from Step 1 represent selection independent of known binding antibodies to avoid any bias, while antibodies from Steps 2 and 3 yield testing antibodies with high similarity to known binding antibodies.

Antibody selection for experimental validation of RSV antibodies

MAGE was prompted using the RSV-A Fusion glycoprotein F0 (UniProt(*53*) entry P03420) amino acid sequence to generate 10,000 sequences for down selection and validation. Basic filtering was applied as described above, along with filtering based on perplexity (PPL < 1.5), heavy chain germline identity (percent VH identity < 98%), and sequence identity to training antibodies (maximum CDRH3 identity to any training antibody ≤ 95%). Due to the overrepresentation of CoV-specific antibodies seen in training, the remaining generated sequences were compared to CoV-AbDab antibodies to remove sequences with CDRH3s similar to CoV-specific antibodies (CDRH3 percent identity > 70%).

Following filtering, antibodies were selected for validation based on three separate criteria groups. First, an unbiased group was selected by clustering generated CDRH3s using hierarchical clustering based on a Levenshtein identity matrix with a maximum identity distance of 20% within each cluster. One sequence was then randomly sampled from each of the top 10 largest clusters, for a total of 10 unbiased sequences selected for validation. For the unbiased group, we selected generated sequences with CDRH3 identity ≥75% and equal CDRH3 length compared RSV-A-specific training antibodies. From these matches, 10 antibodies were randomly selected from unique CDRH3 clusters. Finally, three generated antibodies with CDRH3 identity ≥70% to RSV-A-specific training antibodies and CDRH3 identity ≥60% to MPV-A-specific training antibodies were selected. In total, 23 antibodies were selected for experimental validation.

Antibody selection for experimental validation of H5N1 antibodies

MAGE was prompted using the highly pathogenic avian influenza virus H5/TX/24 hemagglutinin sequence (Strain A/Texas/37/2024, GenBank accession number PP577943.1(*22*)) amino acid sequence as a prompt to generate 1,000 sequences for down selection and validation. Basic filtering was applied as described above, along with filtering based on heavy chain germline identity (percent VH identity < 100%). Antibodies were then selected for validation based on CDRH3 Levenshtein identity to H5-specific training antibodies. Generated sequences were randomly selected from four CDRH3 identity bins: [80% - 85%) (n = 3), [85% - 90%) (n =6), [90% - 95%) (n = 6), and [95% - 99%) (n = 3) for a total of 18 antibodies. Since this exact flu strain sequence was not seen in training, no unbiased group was selected for testing.

Antibody expression and purification

Variable genes were synthesized as cDNA and were inserted into bi-cistronic plasmids encoding for the constant regions of the heavy chain and either the kappa or lambda light chain, for each antibody (Twist BioScience). DH5α cells were transformed with the antibody DNA, and the resulting ampicillin resistant colonies were grown in LB broth. Plasmid DNA was isolated from the bacterial cultures using a plasmid

481 purification kit (Qiagen). The purified antibody DNA was transfected into Expi293F cells using
482 ExpiFectamine transfection reagent (Thermo-Fisher Scientific), and antibodies transiently expressed in
483 FreeStyle F17 expression media (Thermo-Fisher) supplemented 0.1% Pluronic Acid F-68 and 20% 4 mM
484 L-glutamine. Cells were cultured at 8% CO_2 saturation and 37°C with shaking. Cells were collected five
485 days post transfection and centrifuged at a minimum of 5,000 rpm for 20 minutes. Filtered supernatant
486 (Nalgene Rapid Flow Disposable Filter Units with PES membrane 0.45 or 0.22 µm) was purified over
487 protein A equilibrated with PBS. Antibodies were eluted from the column with 100 mM glycine HCl at
488 pH 2.7 directly into a 1:10 volume of 1 M Tris-HCl pH 8 and then buffer exchanged into PBS for storage
489 at 4°C.

490 *Enzyme-linked immunosorbent assay (ELISA)*

491 Recombinant antigen (SARS-CoV-2 Index RBD, SARS-CoV-2 Index S, XBB.1 spike, SARS-CoV-1 S)
492 was plated at 2 ug/mL overnight at 4°C. The next day, plates were washed three times with PBS
493 supplemented with 0.05% Tween20 (PBS-T) and coated with 5% bovine serum albumin (BSA) in PBS-T.
494 Following a one-hour incubation at room temperature, the plates were washed three times with PBS-T.
495 Primary antibodies diluted in 1% BSA in PBS-T were then added to the plates, starting at 10 µg/mL with
496 a serial 1:5 dilution, followed by a one-hour incubation at room temperature. Plates were then washed
497 three times in PBS-T before adding secondary antibody, goat anti-human IgG conjugated to peroxidase, at
498 1:10,000 dilution in 1% BSA in PBS-T followed by a one-hour incubation at room temperature. Plates
499 were washed for a final three times with PBS-T and then developed by adding TMB substrate to each
500 well. Plates were incubated at room temperature for five minutes, and then 1 N sulfuric acid was added to
501 stop the reaction. Plates were read at 450 nm. ELISAs were performed in technical and biological
502 duplicate. The area under the curve (AUC) values were calculated using GraphPad Prism 9.5.0 to fit a 4-
503 parameter log(agonist) vs. response curve.

504 *Antigen expression and purification*

505 For the different binding experiments, SARS-CoV-2 Index S RBD (2019-nCoV) was purchased from
506 Sino Biological catalog number (40592-VNAH) while SARS-CoV-2 S Hexapro Index strain, SARS-CoV-
507 2 S XBB.1, and SARS-CoV-1 S were expressed in Expi293F cells by transient transfection in FreeStyle
508 F17 expression media (Thermo-Fisher) supplemented to a final concentration of 0.1% Pluronic Acid F-68
509 and 20% 4 mM L-glutamine using ExpiFectamine transfection reagent (Thermo-Fisher) cultured for 4-7
510 days at 8% CO_2 saturation and 37°C with shaking. After transfection, cultures were centrifuged at 5000
511 rpm for 20 minutes. Filtered supernatant (Nalgene Rapid Flow Disposable Filter Units with PES
512 membrane 0.45 or 0.22 µm), was run slowly over equilibrated, 1 mL pre-packed StrepTrap XT column
513 (Cytiva Life Sciences). The column was washed with 15 mL of binding buffer (100 mM Tris-HCl, 150
514 mM NaCl, 1 mM EDTA, pH 8.0), and purified protein was eluted from the column with 10 mL of binding
515 buffer supplemented with 2.5 mM desthiobiotin. Protein was concentrated, buffer exchanged into PBS
516 and run on a Superose 6 Increase 10/300 GL on the AKTA FPLC system. Peaks corresponding to trimeric
517 species were identified based on elution volume and SDS-PAGE of elution fractions. Fractions containing
518 pure spike were pooled.

519 **Biolayer interferometry**

520 BLI experiments were performed using an OctetRED96e instrument (Sartorius) at 21°C and a shaking
521 speed of 1000 rpm. For the RBD-binding antibodies, purified SARS-CoV-2 Wuhan- Hu-1 RBD-SD1
522 (residues 319–591) containing a C-terminal 8xHis tag was immobilized to Ni-NTA sensortips (Sartorius)
523 to a response level of approximately 1.5 nm in HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl,
524 0.005% v/v Surfactant P20) with 20 mM imidazole and 0.1% w/v BSA added. After a 60 s baseline step,

immobilized RBD-SD1 was dipped into wells containing 2-fold serial dilutions of IgG ranging in concentration from 32 to 0.5 nM (RBD-159, RBD-238, RBD-409, RBD-839, and RBD-951) or 1024–16 nM (RBD-446) to measure association. 1.5-fold dilutions ranging from 1024 to 90 nM of RBD-61 and a combination of 1.5-fold (1024–303 nM) and 2-fold (303–38 nM) dilutions of RBD-413 were used to optimize the dynamic range of the binding curves for those antibodies. Dissociation was measured by dipping sensortips into wells containing buffer only. Data were reference subtracted and kinetics were calculated (high-affinity antibodies only) by fitting curves to a 1:2 bivalent analyte model using the Octet Data Analysis Software v11.1.

Binding specificity was measured by immobilizing 8xHis-tagged SARS-CoV-2 Wuhan-Hu-1 RBD-SD1 or 8xHis-tagged prefusion-stabilized RSV F trimer (DS-Cav1 (*18*)) to Ni-NTA sensortips to a response level of approximately 1.5 nm in the buffer described above. Immobilized antigen was then dipped into wells containing the anti-RBD IgG of interest (4, 16, or 512 nM antibody for immobilized RBD-SD1 and 512 nM antibody for immobilized RSV F). Immobilized RSV F was also dipped into wells containing only buffer to observe baseline signal drift.

For the RSV F-binding antibodies, purified 8xHis-tagged prefusion-stabilized RSV F trimer (DS-Cav1) was immobilized to Ni-NTA sensortips to a response level of approximately 0.8 nm in HBS-P buffer with 20 mM imidazole and 0.1% w/v BSA added. After a 60 s baseline step, immobilized Ds-Cav1 was dipped into wells containing 2-fold serial dilutions of Fab ranging in concentration from 640 to 10 nM (RSV-2245) or 5 to 0.78 μM (RSV-3301) to measure association. Dissociation was measured by dipping sensortips into wells containing buffer only. Data were reference subtracted and kinetics were calculated by fitting curves to a 1:1 (RSV-2245) or heterogeneous ligand (RSV- 3301) model using the Octet Data Analysis Software v11.1.

SARS-CoV-2 Pseudovirus Neutralization Assay

Pseudovirus neutralization assays were performed as previously described (*56*). Briefly, spike-pseudotyped lentiviruses were produced by the co-transfection of HEK293T cells with respective spike variant plasmids, together with an HIV gag-pol packaging plasmid (Addgene #8455) and a firefly luciferase encoding transfer plasmid (Addgene #170674). Transfections were performed using polyethylenimine. Pseudoviruses titrated to produce approximately 100,000 RLU were incubated with 8 serial 3-fold dilutions for 1 hour at 37°C in black-walled 96-well plates. 10,000 HEK293T-ACE2 cells were then added to each well, and plates were incubated at 37°C. Luminescence was measured approximately 48 hours later on a GloMax Navigator Luminometer (Promega) using Bright-Glo luciferase substrate (Promega) as per the manufacturer's recommendations. Neutralization was calculated relative to the average of 8 control wells infected in the absence of antibody. IC_{50} values were calculated by fitting a four-parameter logistic curve and interpolating the concentration at which there is 50% neutralization, using Prism v10.1.0 (GraphPad Software).

RSV Neutralization Assay

RSV neutralization assays were performed similarly to previously described protocols (PMID: 37403896). In brief, Vero cells were seeded the day before the assay at a density of $2x10^4$ cells per well in a 96-well plate in high glucose DMEM supplemented with L-glutamine and 10% FBS. Monoclonal antibodies were 2-fold serially diluted starting from a concentration of 50 μg/mL in DMEM supplemented with 2% FBS and each antibody dilution was mixed with an equal volume of the same medium containing 100 TCID50 of RSV virus strain A2 (cat n. NR-52018, BEI Resources) and incubated for 1 hour at 37°C, 5% CO_2. Uninfected and infected cell wells without the antibody were also included as controls. After the incubation, the antibody-virus mixtures were added to the cells and plates were incubated at 37°C, 5% CO_2 for 72

570 hours. Plates were then washed with PBS and cells fixed with cold 80% v/v acetone in PBS for 10 minutes
571 at RT. After the incubation, the plates were emptied and washed 3 times with wash buffer (PBS + 0.3%
572 Tween20). Primary mouse anti-RSV F antibody (cat n. MCA490, Bio-Rad) diluted at 1:1,000 in blocking
573 buffer (wash buffer + 7.5% BSA) was then added to the plates and incubated for 1 hour at RT. Following
574 the incubation, the plates were washed 3 times with wash buffer and secondary goat anti-mouse IgG human
575 adsorbed HRP-conjugated secondary antibody (cat. n. 1030-05, Southern Biotech) diluted 1:1,000 was
576 added and incubated for 1 hour in the dark at RT. Plates were then washed 5 times with wash buffer and
577 freshly prepared o-Phenylenediamine dihydrochloride (OPD) substrate added and incubated for 3-5
578 minutes at RT. Reaction was stopped by adding 2N H_2SO_4 and absorbance read at 490 nm using a
579 PowerWaveXS plate reader (BioTek).

580

581 **Influenza reporter virus neutralization assay**

582 Generation of the replication-restricted reporter (R3ΔPB1) H1N1 virus (A/Michigan/45/2015) as well as
583 rewired R3ΔPB1 (R4ΔPB1) H5N1 virus (A/Vietnam/1203/2004) is described elsewhere(*57*). R4ΔPB1
584 H5N1 A/Texas/37/2024 virus was prepared similarly. Briefly, to generate the R3/R4ΔPB1 viruses the viral
585 genomic RNA encoding functional PB1 was replaced with a gene encoding the fluorescent protein
586 (TdKatushka2), and the R3/R4ΔPB1 viruses were rescued by reverse genetics and propagated in the
587 complementary cell line which expresses PB1 constitutively. Each R3/R4ΔPB1 virus stock was titrated by
588 determining the fluorescent units per mL (FU ml^{-1}) prior to use in the experiments. For virus titration, serial
589 dilutions of virus stock in OptiMEM were mixed with pre-washed MDCK-SIAT1-PB1 cells (8×10^5
590 cells/ml) and incubated in a 384-well plate in quadruplicate (25 µl $well^{-1}$). Plates were incubated for 18–26
591 h at 37°C with 5% CO_2 humidified atmosphere. After incubation, fluorescent cells were counted by using
592 a Celigo Image Cytometer (Nexcelom) with a customized red filter for detecting TdKatushka2. For the
593 microneutralization assay, serially diluted antibodies were prepared in OptiMEM and mixed with an equal
594 volume of R3/R4ΔPB1 virus (~8×10^4 FU ml^{-1}) in OptiMEM. After incubation at 37°C and 5% CO_2
595 humidified atmosphere for 1 h, pre-washed MDCK-SIAT1-PB1 cells (8×10^5 cells $well^{-1}$) were added to
596 the antibody-virus mixtures and transferred to 384-well plates in quadruplicate (25 µl $well^{-1}$). Plates were
597 incubated and counted as described above. Target virus control range for this assay is 500 to 2,000 FU per
598 well, and cell-only control is acceptable up to 30 FU per well. The percent neutralization was calculated for
599 each well by constraining the virus control (virus plus cells) as 0% neutralization and the cell-only control
600 (no virus) as 100% neutralization. A 7-point neutralization curve was plotted against antibody concentration
601 for each sample, and a four-parameter nonlinear fit was generated using Prism (GraphPad) to calculate the
602 50% (IC_{50}) inhibitory concentrations.

603 **LIBRA-seq Experiments**

604 For the different LIBRA-seq experiments, a total of 24 proteins were expressed as recombinant soluble
605 antigens. Influenza, parainfluenza, coronavirus, RSV post fusion, hMPV post fusion, and HIV-1 antigens
606 were expressed as described above and then purified over the appropriate affinity column at 4°C.

607 Recombinant hemagglutinin (HA) proteins all contained the HA ectodomain with a point mutation at the
608 sialic acid-binding site (Y98F), a T4 fibritin foldon trimerization domain, and a hexahistidine-tag. HAs
609 were purified by metal affinity chromatography. Parainfluenza virus type 3 prefusion stabilized F
610 ectodomain (PDB: 6MJZ) was purified by nickel affinity chromatography. SARS-CoV-2 S XBB.1,
611 BQ.1.1, SARS-CoV-1 S, HCoV-OC43 S, HCoV-HKU1-S-2P, RSV post fusion, and hMPV post fusion
612 were purified over pre-packed StrepTrap XT column (Cytiva Life Sciences), as described above. Single

613 chain HIV-1 gp140 SOSIP variant strain BG505(*58*) was purified over agarose bound Galanthus nivalis
614 lectin (Vector Laboratories cat no. AL-1243-5). Methods have been previously described.(*59*)

615 Previously described hMPV F A1(NL/1/00) and B2(TN99-419) antigens were expressed in FreeStyle
616 293-F cells by transient transfection in FreeStyle 293 expression media (Thermo-Fisher). Cells were co-
617 transfected at a 4:1 ratio of plasmids encoding human metapneumovirus F and furin, respectively, using
618 polyethylenimine (PEI). Three hours post-transfection, media was supplemented to a final concentration
619 of 0.1% (v/v) Pluronic Acid F-68. After culturing for 6 days at 37°C and 8% CO_2 saturation, filtered
620 supernatant was concentrated and buffer exchanged to PBS using tangential flow filtration. Samples were
621 then run over a gravity-flow affinity column at room temperature. Previously described RSV F (DS-Cav1)
622 A2 and B9320 antigens were expressed similarly but did not include the Pluronic F-68 supplementation
623 step. Stabilized ectodomains of hMPV F subtypes A1 and B2(*60*) , as well as RSV strains A2(*18, 61*) and
624 B9320 F (DS-Cav1(*62*)), were purified over Strep-Tactin Sepharose resin (IBA Lifesciences) in a gravity
625 column.

626 CHDC, SYD_2012, and GII.17 P domains were recombinantly expressed and purified as previously
627 described(*63*).

628 All proteins were quantified using UV/vis spectroscopy. Antigenicity of proteins was characterized by
629 ELISA with known monoclonal antibodies specific for that antigen. Proteins were frozen and stored at -
630 80°C until use.

631 *Donor peripheral blood mononuclear cell (PBMCs) samples*

632 Healthy peripheral blood mononuclear cell (PBMC) samples were purchased from StemCell
633 Technologies. SARS-CoV-2 PBMCs were collected from individuals with SARS-CoV-2 infection,
634 60 days post symptom onset during May-June 2020. Influenza vaccination PBMCs were collected from
635 individuals 28 days following vaccination with the 2021-2022 quadrivalent flu vaccine. HIV-1 PBMCS
636 were collected between 2007-2013 from individuals with confirmed HIV-1 status.

637 *Conjugation of oligonucleotide barcodes to antigens for LIBRA-seq*

638 For each antigen, a unique DNA barcode was directly conjugated to the antigen using a SoluLINK
639 Protein-Oligonucleotide Conjugation kit (TriLink, S-9011) according to manufacturer's protocol.

640 *Biotinylation of antigens for LIBRA-seq*

641 Protein antigens were biotinylated using EZ-link Sulfo-NHS-Biotin No-Weigh kit (Thermo Fisher)
642 according to manufacturer's instructions. A 50:1 biotin-to-protein molar ratio was used for all reactions.

643 *Flow cytometry enrichment of antigen-specific B cells*

644 For a given sample, cell mixtures were stained and mixed with fluorescently labeled DNA-barcoded
645 antigens and other antibodies, and then sorted using fluorescence activated cell sorting (FACS). Cells
646 were counted, washed with DPBS supplemented with 0.1% Bovine serum albumin (BSA), and
647 resuspended in DPBS-BSA to be stained with the following cell markers: Ghost Red 780, CD14-
648 APCCy7, CD3-FITC, CD19-BV711, and IgG-PECy5. Additionally, antigen-oligo conjugates were added
649 to the stain. Following a 30-minute incubation in the dark on ice, the cells were washed three times with
650 DPBS-BSA then incubated for 15 minutes in the dark on ice with Streptavidin-PE label cells with bound
651 antigen. Cells were then resuspended in DPBS-BSA and sorted on the cell sorter. Antigen positive cells
652 were bulk sorted and then delivered to the Vanderbilt VANTAGE sequencing core at an appropriate target

653 concentration for 10X Genomics library preparation and subsequent sequencing. FACS data were
654 analyzed using FlowJo.

655 *Sequence processing and bioinformatics analysis for LIBRA-seq.*

656 We followed our established pipeline (*13*), which takes paired-end FASTQ files of oligonucleotide
657 libraries as input, to process and annotate reads for cell barcodes, unique molecular identifiers (UMIs) and
658 antigen barcodes, resulting in a cell barcode-antigen barcode UMI count matrix. B cell receptor contigs
659 were processed using CellRanger 3.1.0 (10x Genomics) and GRCh38 Human V(D)J 7.0.0 as reference,
660 while the antigen barcode libraries were also processed using CellRanger (10x Genomics). The cell
661 barcodes that overlapped between the two libraries formed the basis of the subsequent analysis. Cell
662 barcodes that had only non-functional heavy chain sequences as well as cells with multiple functional
663 heavy chain sequences and/or multiple functional light chain sequences, were eliminated, reasoning that
664 these may be multiplets. We also aligned the B cell receptor contigs to IMGT reference genes using
665 HighV-Quest(*64*). The annotated sequences were then combined with an antigen barcode UMI count
666 matrix. Finally, we determined the LIBRA-seq score (LSS) for each antigen in the library for every cell as
667 previously described(*13*). Binding was defined using a conservative threshold of LSS ≥ 2, based on
668 validation results from previous LIBRA-seq studies. Cells which bound to multiple antigens from
669 different viral families were filtered out to remove polyreactive BCRs, along with any cells from non-HIV
670 donors which bound HIV antigens.

671 *Cryo-EM sample prep and data collection*

672 RSV F (prefusion-stabilized, PR-DM(*27*) was mixed to a final concentration of 2.5 mg/mL with 1.5X
673 molar excess of Fabs RSV-2245 and RSV-3301 in buffer containing 2 mM Tris pH 7.5, 200 mM NaCl,
674 0.02% NaN_3. The complex was incubated for 30 minutes at 4 °C before adding 10X CMC CHAPS
675 (VitroEase™ Buffer Screening Kit, Thermo Fisher) to a final concentration of 0.1X CMC. Immediately
676 following the addition of CHAPS, 3.5 µL of sample was applied to C-flat 1.2/1.3 300 mesh grids
677 (Electron Microscopy Sciences) that had been glow discharged using a PELCO easiGlow (Ted Pella) for
678 30 seconds at a current of 20 mA. Using a Vitrobot Mark IV (Thermo Fisher), a blot force of 1 was
679 applied for 9 s to blot away excess liquid before plunge-freezing into liquid ethane. Samples were blotted
680 in 100% humidity at 4 °C.

681 1,561 movies were collected from a single grid using a Glacios TEM (Thermo Fisher) equipped with a
682 Falcon 4 detector (Thermo Fisher), with the stage tilted to 30°. All movies were collected using SerialEM
683 v4.0.10 automation software(*65*). Particles were imaged at a calibrated magnification of 0.933 Å/pixel,
684 with an exposure of 2.5 eps for 17s for a total exposure of 49 e/Å2. Additional details about data
685 collection parameters can be found in Supplementary Table 3.

686 Cryo-EM processing and structure building

687 Motion correction, CTF estimation, particle picking, and preliminary 2D classification were performed
688 using cryoSPARC v4.6.0 live processing(*66*) (Supplementary Figure 1 workflow). An initial ab initio
689 reconstruction of four classes was performed during live processing using 123,151 particles. Once data
690 collection was completed, a final iteration of 2D class averaging distributed 610,184 particles into 80
691 classes using an uncertainty factor of 1 and a batchsize of 300 for 25 iterations. From that, 338,721
692 particles were selected and carried into a heterogeneous refinement of the four volumes that resulted from
693 the initial ab initio reconstruction. Particles from the highest quality class were used for homogenous
694 refinement of the best volume with applied C3 symmetry. To address remaining particle heterogeneity,
695 210,844 particles (after re-extraction and duplicate removal) were sorted into four classes by performing

another Ab initio reconstruction, followed by heterogeneous refinement of the four classes using all particles. From this, 140,634 particles were taken from the best class and used for a final non-uniform refinement with applied C3 symmetry and with refined per-particle defocus and per-group CTF parameters(*67*). To improve map quality, the refinement volumes were processed using DeepEMhancer(*68*) within cryoSPARC(*66*) [cite]. An initial model of the complex was generated using AlphaFold 3 (https://alphafoldserver.com) by inputting sequences (separately) for RSV F1 and F2, 2245 VH and VL, and 3301 VH and VL(*69*). The highest confidence output model was docked into the refined volume via ChimeraX v1.8(*70*). The structure was iteratively refined and completed using a combination of Phenix v1.21.2(*71*), Coot v0.9.2(*72*), and ISOLDE v1.8(*73*).

References

1. W. Ding, K. Nakai, H. Gong, Protein design via deep learning. *Briefings in Bioinformatics* **23**, (2022).
2. H. Wang *et al.*, Scientific discovery in the age of artificial intelligence. *Nature* **620**, 47-60 (2023).
3. J. A. Ruffolo, L.-S. Chu, S. P. Mahajan, J. J. Gray, Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. *Nature Communications* **14**, 2389 (2023).
4. R. W. Shuai, J. A. Ruffolo, J. J. Gray, IgLM: Infilling language modeling for antibody sequence design. *Cell Syst* **14**, 979-989.e974 (2023).
5. E. Nijkamp, J. A. Ruffolo, E. N. Weinstein, N. Naik, A. Madani, ProGen2: Exploring the boundaries of protein language models. *Cell Systems* **14**, 968-978.e963 (2023).
6. X. Xu *et al.*, AB-Gen: Antibody Library Design with Generative Pre-trained Transformer and Deep Reinforcement Learning. *Genomics, Proteomics & Bioinformatics* **21**, 1043-1053 (2023).
7. B. L. Hie *et al.*, Efficient evolution of human antibodies from general protein language models. *Nat Biotechnol* **42**, 275-283 (2024).
8. T. A. Desautels *et al.*, Computationally restoring the potency of a clinical antibody against Omicron. *Nature*, (2024).
9. A. Shanehsazzadeh *et al.*, In vitro validated antibody design against multiple therapeutic antigens using generative inverse folding. *bioRxiv*, 2023.2012.2008.570889 (2023).
10. M. Haraldson Høie *et al.*, AntiFold: Improved antibody structure-based design using inverse folding. 2024 (10.48550/arXiv.2405.03370).
11. B. L. Hie *et al.*, Efficient evolution of human antibodies from general protein language models. *Nature Biotechnology* **42**, 275-283 (2024).
12. N. R. Bennett *et al.*, Atomically accurate de novo design of single-domain antibodies. *bioRxiv*, 2024.2003.2014.585103 (2024).
13. I. Setliff *et al.*, High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell* **179**, 1636-1646.e1615 (2019).
14. M. P. Lefranc *et al.*, IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res* **37**, D1006-1012 (2009).
15. D. Prihoda *et al.*, BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. *MAbs* **14**, 2020203 (2022).
16. D. Pinto *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290-295 (2020).
17. D. Apiyo, "Biomolecular Binding Kinetics Assays on the Octet® BLI Platform," (2022).
18. J. S. McLellan *et al.*, Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science* **342**, 592-598 (2013).
19. E. C. Chen *et al.*, Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. *Cell Rep* **36**, 109604 (2021).
20. I. Setliff *et al.*, Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. *Cell Host Microbe* **23**, 845-854.e846 (2018).
21. S. C. Wall *et al.*, SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes. *Cell Reports Medicine* **4**, 101267 (2023).
22. T. M. Uyeki *et al.*, Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Dairy Farm Worker. *New England Journal of Medicine* **390**, 2028-2029 (2024).
23. Y. Medina-Armenteros, D. Cajado-Carvalho, R. das Neves Oliveira, M. Apetito Akamatsu, P. Lee Ho, Recent Occurrence, Diversity, and Candidate Vaccine Virus Selection for Pandemic H5N1: Alert Is in the Air. *Vaccines* **12**, 1044 (2024).
24. M. G. Joyce *et al.*, Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. *Cell* **166**, 609-623 (2016).

25. M. Yuan *et al.*, Structural basis of a shared antibody response to SARS-CoV-2. *Science* **369**, 1119-1123 (2020).
26. C. Dreyfus *et al.*, Highly conserved protective epitopes on influenza B viruses. *Science* **337**, 1343-1348 (2012).
27. A. Krarup *et al.*, A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. *Nature communications* **6**, 8143 (2015).
28. M. S. Gilman *et al.*, Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. *Sci Immunol* **1**, (2016).
29. J. A. Lopez *et al.*, Antigenic structure of human respiratory syncytial virus fusion glycoprotein. *Journal of virology* **72**, 6922-6928 (1998).
30. L. Anderson, J. C. Hierholzer, Y. Stone, C. Tsou, B. Fernie, Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. *Journal of clinical microbiology* **23**, 475-480 (1986).
31. I. Rossey, J. S. McLellan, X. Saelens, B. Schepens, Clinical potential of prefusion RSV F-specific antibodies. *Trends in microbiology* **26**, 209-219 (2018).
32. D. A. Dougan, R. L. Malby, L. C. Gruen, A. A. Kortt, P. J. Hudson, Effects of substitutions in the binding surface of an antibody on antigen affinity. *Protein Eng* **11**, 65-74 (1998).
33. K. Winkler *et al.*, Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody. *The Journal of Immunology* **165**, 4505-4514 (2000).
34. J. Foote, G. Winter, Antibody framework residues affecting the conformation of the hypervariable loops. *Journal of molecular biology* **224**, 487-499 (1992).
35. F. Klein *et al.*, Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell* **153**, 126-138 (2013).
36. I. Rossey *et al.*, A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody. *Journal of virology* **95**, 10.1128/jvi. 02279-02220 (2021).
37. S. Bubeck *et al.*, Sparks of artificial general intelligence: Early experiments with gpt-4. *arXiv preprint arXiv:2303.12712*, (2023).
38. H. Naveed *et al.*, A comprehensive overview of large language models. *arXiv preprint arXiv:2307.06435*, (2023).
39. A. Power, Y. Burda, H. Edwards, I. Babuschkin, V. Misra, Grokking: Generalization beyond overfitting on small algorithmic datasets. *arXiv preprint arXiv:2201.02177*, (2022).
40. M. I. J. Raybould, A. Kovaltsuk, C. Marks, C. M. Deane, CoV-AbDab: the coronavirus antibody database. *Bioinformatics* **37**, 734-735 (2020).
41. J. Dunbar *et al.*, SAbDab: the structural antibody database. *Nucleic Acids Research* **42**, D1140-D1146 (2013).
42. B. Abanades *et al.*, The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures. *Nucleic Acids Research* **52**, D545-D551 (2023).
43. S. A. Ehrhardt *et al.*, Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. *Nature Medicine* **25**, 1589-1600 (2019).
44. Z. A. Bornholdt *et al.*, Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. *Science* **351**, 1078-1083 (2016).
45. Y. Liu *et al.*, Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. *Nature Communications* **10**, 324 (2019).
46. S. F. Andrews *et al.*, Immune history profoundly affects broadly protective B cell responses to influenza. *Sci Transl Med* **7**, 316ra192 (2015).
47. T. Weber *et al.*, Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. *Immunity* **55**, 341-354.e347 (2022).
48. L. M. Walker *et al.*, High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. *Front Immunol* **13**, 855772 (2022).

49. A. R. Shiakolas *et al.*, Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. *Nature Biotechnology* **40**, 1270-1275 (2022).
50. A. R. Shiakolas *et al.*, Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. *Cell Reports Medicine* **2**, 100313 (2021).
51. E. C. Chen *et al.*, Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. *Cell Rep* **42**, 112370 (2023).
52. A. Shanehsazzadeh *et al.*, Unlocking de novo antibody design with generative artificial intelligence. *bioRxiv*, 2023.2001.2008.523187 (2024).
53. T. U. Consortium, UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic Acids Research* **51**, D523-D531 (2022).
54. F. Teufel *et al.*, SignalP 6.0 predicts all five types of signal peptides using protein language models. *Nature Biotechnology* **40**, 1023-1025 (2022).
55. J. Dunbar, C. M. Deane, ANARCI: antigen receptor numbering and receptor classification. *Bioinformatics* **32**, 298-300 (2015).
56. D. J. Sheward *et al.*, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. *Lancet Infect Dis* **22**, 1538-1540 (2022).
57. A. Creanga *et al.*, A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. *Nature Communications* **12**, 1722 (2021).
58. I. S. Georgiev *et al.*, Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. *J Virol* **89**, 5318-5329 (2015).
59. A. A. Abu-Shmais *et al.*, Antibody sequence determinants of viral antigen specificity. *mBio* **0**, e01560-01524.
60. S. A. Rush *et al.*, Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus. *Cell Rep* **40**, 111399 (2022).
61. J. S. McLellan *et al.*, Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.
62. Q. Zhu *et al.*, A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. *Sci Transl Med* **9**, (2017).
63. M. M. Leuthold, A. D. Koromyslova, B. K. Singh, G. S. Hansman, Production of Human Norovirus Protruding Domains in E. coli for X-ray Crystallography. *JoVE*, e53845 (2016).
64. X. Brochet, M. P. Lefranc, V. Giudicelli, IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. *Nucleic Acids Res* **36**, W503-508 (2008).
65. D. N. Mastronarde, Automated electron microscope tomography using robust prediction of specimen movements. *Journal of structural biology* **152**, 36-51 (2005).
66. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nature methods* **14**, 290-296 (2017).
67. J. L. Rubinstein, M. A. Brubaker, Alignment of cryo-EM movies of individual particles by optimization of image translations. *Journal of structural biology* **192**, 188-195 (2015).
68. R. Sanchez-Garcia *et al.*, DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. *Communications biology* **4**, 874 (2021).
69. J. Abramson *et al.*, Accurate structure prediction of biomolecular interactions with AlphaFold 3. *Nature*, 1-3 (2024).
70. E. F. Pettersen *et al.*, UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein science* **30**, 70-82 (2021).
71. P. D. Adams *et al.*, PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallographica Section D: Biological Crystallography* **58**, 1948-1954 (2002).
72. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. *Acta crystallographica section D: biological crystallography* **60**, 2126-2132 (2004).

73. T. I. Croll, ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallographica Section D: Structural Biology* **74**, 519-530 (2018).